Skip to content

Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease

Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease (ADHERE-ASCVD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07522645
Acronym
ADHERE-ASCVD
Enrollment
22000
Registered
2026-04-13
Start date
2026-04-14
Completion date
2028-12-31
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ASCVD, Diabetes

Keywords

ASCVD, ASCVD management, statin therapy, statin, SMART design, messaging strategies, patient outreach

Brief summary

The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are: 1. Do different outreach methods (such as text messages, secure portal messages, or email) increase short-term statin refill compared to usual care? 2. Among patients who do not initially refill their prescription, does changing the outreach method improve refill rates? The team with operational partners will evaluate the comparitive effectivessness of multiple messaging strategies delivered through existing health system communication channels, including SMS (text messaging), secure patient portal messages, non-secure email, and usual care (no additional outreach). Participants * Receive an initial outreach message encouraging statin refill (or usual care) Be monitored for statin refill within 14 days * Potentially receive a second outreach message using the same or a different communication method if they do not initially refill their prescription * Have their medication refill patterns tracked over time, including longer-term adherence outcomes

Detailed description

Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death worldwide. Statins can reduce ASCVD events by 25%, yet nearly half of high-risk adults remain untreated, and adherence is poor. Since statin adherence impacts quality metrics like Medicare Stars ratings, even small gains in refill rates can boost health plan performance. However, no data driven approaches exist to optimize statin adherence. The ADHERE-ASCVD study is a pragmatic, Prospective Randomized Open-label Blinded End-point (PROBE) randomized clinical trial designed to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence. The project leverages a two-stage Sequential Multiple Assignment Randomized Trial (SMART) design to evaluate both initial outreach strategies and adaptive follow-up approaches among patients with suboptimal statin adherence. In the first stage, eligible participants will be randomized to one of four outreach strategies: secure portal message, SMS (text message), non-secure email, or usual care (no proactive outreach). The primary response window is 14 days following message delivery, during which statin refill will be ascertained using pharmacy dispensing records. Participants who refill within this window will be classified as responders and will not receive further study intervention. Participants who do not refill within 14 days will be classified as non-responders and re-randomized in a second stage to receive one of three follow-up strategies: (1) continued outreach using the same communication modality ("stay"), (2) outreach using an alternative modality ("switch"), or (3) usual care with no additional outreach. For the initial implementation phase, message content will remain consistent across stages within each modality, and the intervention focuses on evaluating modality and sequencing rather than content optimization. The primary estimands correspond to (1) first-stage effects comparing outreach modalities, (2) conditional second-stage effects among non-responders comparing stay, switch, and usual care strategies, and (3) dynamic treatment regime (DTR) effects comparing embedded adaptive sequences of interventions. DTR effects will be estimated using inverse-probability-weighted estimators that account for sequential randomization. In addition to estimating average treatment effects, the study will develop predictive models to characterize treatment effect heterogeneity across patient subgroups. The modeling framework focuses on estimating differences in response across messaging strategies conditional on baseline patient characteristics. Model evaluation will emphasize calibration of predicted treatment contrasts and the identification of clinically meaningful differences between strategies that can inform targeted outreach. This study is designed to generate actionable evidence within a learning health system by identifying optimal messaging strategies and sequences for improving statin refill and adherence, and enabling future deployment of targeted, data-driven outreach approaches.

Interventions

BEHAVIORALSMS (Initial Outreach)

Participants will receive an initial SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.

BEHAVIORALSecure Portal Message (Initial Outreach)

Participants will receive an initial secure message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.

BEHAVIORALNon-secure Email (Initial Outreach)

Participants will receive an initial non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.

BEHAVIORALSMS (Follow-up for Non-responders)

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.

BEHAVIORALSecure Portal Message (Follow-up for Non-responders)

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up secure portal message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.

BEHAVIORALNon-secure Email (Follow-up for Non-responders)

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.

Sponsors

Kaiser Permanente
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Two-stage, sequential multiple assignment randomized trial (SMART)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18 years 2. Active Kaiser Permanente Northern California (KPNC) membership 3. Diagnosis of atherosclerotic cardiovascular disease (ASCVD) or diabetes and inclusion in the Preventing Heart Attacks and Strokes Everyday (PHASE) Registry 4. No statin prescription fill within the prior 3 months 5. Statin adherence \<80% in the prior 12 months 6. Active kp.org account within the past 12 months 7. Valid email address and text-capable phone number on file

Exclusion criteria

1. Documented allergic reaction or contraindication to statin therapy 2. Receiving hospice care 3. Medicare beneficiaries 4. Other exclusions applied per operational standard practice

Design outcomes

Primary

MeasureTime frameDescription
Statin refill after message deliveryWithin 14 days after each stage of message deliveryProportion of participants who refill a statin prescription following message delivery (first-stage intervention) or, among non-responders, following second-stage messaging. Refill status will be determined using pharmacy dispensing records.

Secondary

MeasureTime frameDescription
Time to statin refillUp to 30 days after each stage of message deliveryTime from message delivery (first-stage or second-stage, as applicable) to statin refill, measured using pharmacy dispensing records. Participants who do not refill will be censored at disenrollment, death, or end
Statin refillWithin 30 days after message deliveryProportion of participants who refill a statin prescription following message delivery (first-stage or second-stage, as applicable), based on pharmacy dispensing records.
Statin persistenceAt 6 months and 12 months post randomization.Proportion of participants who remain persistent with statin therapy, defined as continuous statin use without a gap exceeding 60 days between prescription fills.
Statin adherence (proportion of days covered)At 6 months and 12 months post randomization.Adherence to statin therapy measured as the proportion of days covered (PDC), defined as the number of days with statin supply available divided by the number of days in the observation period. Adherence will be assessed as both a continuous measure and as a binary indicator using a threshold of ≥80%.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 31, 2026